Servier’s Olivier Laureau: Change Instigator
Not long ago, Laboratories Servier was considered a somewhat mysterious and opaque actor on the world…
European MidPharmas – R&D based pharmaceutical companies with annual revenues of between EUR 50 million and 5 billion – are having to be increasingly focused and resilient to succeed and fend off their inherent vulnerabilities according to a new report from specialist pharma and biotech consultancy Novasecta. Focus 75…
Not long ago, Laboratories Servier was considered a somewhat mysterious and opaque actor on the world…
In view of the manifold hurdles encountered when attempting to raise capital, Switzerland’s medium capitalized…
Despite the Spanish economy and pharmaceutical market’s steady growth, many local players are becoming cognizant…
Bringing together insights from the heads of some of Europe’s most prominent mid-cap pharma firms. The…
The European MidPharma Performance Ranking 2019 is taken from The Novasecta European Midpharma Report 2019, which…
Iconic French skincare specialist, Pierre Fabre has been enjoying a hot streak of late, with its dermo-cosmetics…
Denis Delval, CEO of iconic French pharma firm LFB since December 2017,…
Antonio Portela, seven years into leading the Bial operation in Portugal, shares…
Markus Sieger, CEO of Polpharma, outlines his global strategy for the company,…
Esteve has long been a family-run business, though in early 2018 the Spanish…
The Chairman of Ferring’s Group Operating Committee and Senior Vice President…
